The Role of the PI3K/AKT/mTOR (PAM) Pathway in Breast Cancer: Mechanisms and Therapeutic Implications

Introduction

Breast cancer is the most commonly diagnosed cancer in women worldwide, with diverse molecular subtypes influencing prognosis and treatment response. Among the key signaling pathways implicated in breast cancer progression, the PI3K/AKT/mTOR (PAM) pathway plays a central role in tumor growth, survival, and resistance to therapy. Dysregulation of this pathway is frequently observed in breast cancer, making it a critical target for precision medicine.

The PAM Pathway: An Overview

The PAM pathway consists of three major components:

1. Phosphoinositide 3-kinase (PI3K) – Activates signaling by phosphorylating PIP2 to PIP3.

2. AKT (Protein Kinase B) – A key mediator that promotes cell survival, proliferation, and metabolism.

3. mTOR (Mammalian Target of Rapamycin) – Regulates protein synthesis and cell growth in response to nutrients and growth signals.

This pathway is tightly regulated by the tumor suppressor PTEN (Phosphatase and Tensin Homolog), which dephosphorylates PIP3, inhibiting pathway activation.

PAM Pathway Alterations in Breast Cancer

Dysregulation of the PAM pathway occurs through multiple mechanisms in breast cancer, including:

• PIK3CA mutations (30-40% of hormone receptor-positive/HER2-negative breast cancers)

• PTEN loss or mutation (leading to hyperactivation of AKT)

• AKT amplifications or mutations

• mTOR overactivation (promoting uncontrolled cell growth)

These alterations contribute to:
✔ Enhanced cell proliferation and survival
✔ Resistance to chemotherapy and endocrine therapy
✔ Metabolic reprogramming (Warburg effect)
✔ Increased angiogenesis and metastasis

PAM Pathway in Different Breast Cancer Subtypes

1. HR+/HER2- Breast Cancer

   • PIK3CA mutations are common, leading to endocrine resistance (e.g., tamoxifen or aromatase inhibitors).

   • mTOR inhibitors (e.g., everolimus) are used in combination with hormonal therapy.

2. HER2-Positive Breast Cancer

   • HER2 signaling cross-activates PI3K/AKT, contributing to trastuzumab resistance.

   • Dual HER2/PI3K inhibition is being explored in clinical trials.

3. Triple-Negative Breast Cancer (TNBC)

   • PTEN loss and AKT activation are frequent, making AKT inhibitors a potential therapeutic strategy.

Therapeutic Targeting of the PAM Pathway

Several drugs targeting the PAM pathway have been developed:

• PI3K inhibitors (e.g., alpelisib, approved for PIK3CA-mutated HR+/HER2- breast cancer)

• AKT inhibitors (e.g., capivasertib, showing promise in clinical trials)

• mTOR inhibitors (e.g., everolimus, used in combination with exemestane)

However, challenges remain, including toxicity, resistance mechanisms, and pathway feedback loops.

Future Directions

• Biomarker-driven therapies (identifying PIK3CA, PTEN, or AKT alterations for personalized treatment).

• Combination therapies (e.g., PI3K inhibitors + immunotherapy in TNBC).

• Novel inhibitors with better selectivity and fewer side effects.

Conclusion

The PAM pathway is a crucial driver of breast cancer progression and therapy resistance. Targeting this pathway has shown clinical benefits, but further research is needed to overcome resistance and improve patient outcomes. Precision medicine approaches, guided by genomic profiling, will be essential in optimizing PAM-targeted therapies for breast cancer patients.